Class 4 Medicines Defect Information: Atnahs Pharma UK, Zestoretic 20mg/12.5mg Tablets, EL (23)A/05
Atnahs Pharma UK has informed the MHRA that the Patient Information Leaflet (PIL) packaged in certain batches of Zestoretic 20mg/12.5mg Tablets contains outdated safety information.
MDR number
MDR 143-02/23
Company name
Atnahs Pharma UK
Product name
Zestoretic 20mg/12.5mg Tablets, PL 43252/0035
SNOMED Code
17403011000001101
| Batch No | Expiry Date | Pack Size | First Distributed |
|---|---|---|---|
| SB012 | Apr 2024 | 28 units | 7 Sep 2022 |
Active Pharmaceutical Ingredient: Lisinopril and Hydrochlorothiazide
Brief description of the issue
Atnahs Pharma UK has informed the MHRA that the Patient Information Leaflet (PIL) packaged in the above batch of Zestoretic 20mg/12.5mg Tablets contains outdated safety information. Healthcare professionals should note that the critical missing information is contained within Section 4 of the incorrect PIL, however it is not in line with the recommended update to the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL). It omits specific text to alert prescribers and patients to new information that relates to a side effect classified as having a very rare frequency (less than 1 in 10,000). Details of the discrepancies are listed below:
Section 2
‘If you experienced breathing or lung problems (including inflammation or fluid in the lungs) following hydrochlorothiazide intake in the past. If you develop any severe shortness of breath or difficulty breathing after taking Zestoretic, seek medical attention immediately’.
Section 4
‘Acute respiratory distress (signs include severe shortness of breath, fever, weakness, and confusion)’.
The SmPC and PIL are up to date:
- Zestoretic 20mg/12.5mg Tablets - PL 43252/0035 – SmPC
- Zestoretic 20mg/12.5mg Tablets - PL 43252/0035 – PIL
Full text link for SmPC:
https://mhraproducts4853.blob.core.windows.net/docs/a5b5e2b8d78e4b987c88906b899fa759f0394bb5
Full text link for PIL:
https://mhraproducts4853.blob.core.windows.net/docs/aa4ecef3f6ff1689a1d571ca3c53009157d05eb4
Advice for healthcare professionals
There is no risk to product quality as a result of this issue. Healthcare professionals are advised to exercise caution when dispensing the above batches of the product. Where possible, please provide an updated copy of the PIL to the patient and remind the patient to read the leaflet in its entirety before using the medicine. This is available via the following link: Zestoretic 20mg/12.5mg Tablets - PL 43252/0035 – PIL
Where available, Atnahs Pharma UK will be providing the updated PIL with all future deliveries of Zestoretic 20mg/12.5mg Tablets. Upon request, Atnahs Pharma UK will post hard copies of the updated PIL to wholesalers and pharmacies so that any remaining stock in the dispensary can be supplemented with the correct PIL information.
Advice for patients
Patients should be aware that the PIL in the Zestoretic 20mg/12.5mg Tablets batch SB012 does not contain the most up-to-date safety information. The missing information is listed below. Patients should be aware that Section 4 of the incorrect PIL contains information on serious side effects, but does not elaborate on these side effects. Details of the missing information is included below:
Section 2
‘If you experienced breathing or lung problems (including inflammation or fluid in the lungs) following hydrochlorothiazide intake in the past. If you develop any severe shortness of breath or difficulty breathing after taking Zestoretic, seek medical attention immediately’.
Section 4
‘Acute respiratory distress (signs include severe shortness of breath, fever, weakness, and confusion)’.
Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should be reported via the MHRA Yellow Card scheme.
Further Information
For more information, medical information queries, replacement PIL enquiries and stock control queries, please contact: [email protected]
Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.
Yours faithfully
Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU
Telephone +44 (0)20 3080 6574
Email: [email protected]
Download document